Clinical trial for Cancer
Official title A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
ClinicalTrials.gov ID: NCT06835569
What this study is testing
What is ALTA3263?
An investigational oral medicine being studied as a potential treatment for advanced solid tumors with KRAS mutations. It is designed to selectively inhibit mutant KRAS proteins that drive tumor growth.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study is looking at how safe ALTA3263 is and how well people can tolerate it.
- Who it's for
- Adults who have advanced solid tumors such as pancreatic, lung, or colorectal cancer with a KRAS mutation.
- What's involved
- Participants will receive ALTA3263 and undergo regular check‑ups, lab tests, and imaging to monitor safety.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically confirmed diagnosis of a solid tumor malignancy harboring a KRAS mutation identified through molecular testing (NGS- or PCR-based)...
- Unresectable or metastatic disease.
- Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and...
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function
You likely can't join if
- Prior treatment with a KRAS inhibitor, certain exceptions are described in the full study protocol
- Known condition that prohibits the ability to swallow or absorb an oral medication. Other inclusion/exclusion criteria may apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Orlando, Florida, United States
- Tampa, Florida, United States
- Boston, Massachusetts, United States
- St Louis, Missouri, United States
- New York, New York, United States
- Durham, North Carolina, United States
- Nashville, Tennessee, United States
- Houston, Texas, United States
- San Antonio, Texas, United States
- Fairfax, Virginia, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Orlando, Florida, United States; Tampa, Florida, United States; Boston, Massachusetts, United States; St Louis, Missouri, United States; New York, New York, United States; Durham, North Carolina, United States and 4 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.